World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
78
Citations
23899
World Ranking
17991
National Ranking
727

Overview

Sabino De Placido is affiliated with the University of Naples Federico II in Italy. Their research contributions span multiple areas within Medicine, with particular emphasis on Oncology and related fields. They have authored a significant body of work in the domains of Biochemistry, Genetics and Molecular Biology.

The main fields of study covered in their publications include:

  • Medicine
  • Biochemistry, Genetics and Molecular Biology

Within these broader fields, their subfields of specialization are:

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research
  • Neurology
  • Surgery

The primary research topics addressed in their work encompass:

  • Advanced Breast Cancer Therapies
  • Breast Cancer Treatment Studies
  • Cancer Treatment and Pharmacology
  • HER2/EGFR in Cancer Research
  • Myasthenia Gravis and Thymoma
  • Cancer Genomics and Diagnostics
  • BRCA gene mutations in cancer

Some of the recent published papers include:

  • Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer (2021, Annals of Oncology)
  • Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer (2021, npj Breast Cancer)
  • Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial (2022, Journal of Clinical Oncology)
  • HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis (2020, Cancer Treatment Reviews)
  • Toll-Like Receptors and COVID-19: A Two-Faced Story with an Exciting Ending (2020, Future Science OA)

The venues frequently chosen for publication reflect the scientist's research focus and include:

  • Annals of Oncology
  • Mediastinum
  • ESMO Open
  • Journal of Clinical Oncology
  • Cancers

Frequent co-authors in their publications are:

  • Pietro De Placido
  • Grazia Arpino
  • Mario Giuliano
  • Lucia Del Mastro
  • Erica Pietroluongo

Best Publications

  • A new prognostic system for hepatocellular carcinoma: A retrospective study of 435 patients

    Giuseppe Manghisi;Silvana Elba;Ascanio Mossa;Antonio Giorgio

  • Inhibition of Growth Factor Production and Angiogenesis in Human Cancer Cells by ZD1839 (Iressa), a Selective Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor,

    Fortunato Ciardiello;Rosa Caputo;Roberto Bianco;Vincenzo Damiano

  • Prospective validation of the CLIP score, a new prognostic system for cirrhotic patients with hepatocellular carcinoma (RE: Hepatology 2000, 32/3: 679-80)

    Izzo Francesco;Oreste Cuomo;Gaetano Capuano;Giuseppe Ruggiero

  • Estrogen Receptor–Positive, Progesterone Receptor–Negative Breast Cancer: Association With Growth Factor Receptor Expression and Tamoxifen Resistance

    Grazia Arpino;Heidi Weiss;Adrian V. Lee;Rachel Schiff

  • Expression of Epidermal Growth Factor Receptor Correlates with Disease Relapse and Progression to Androgen-independence in Human Prostate Cancer

    Giuseppe Di Lorenzo;Giampaolo Tortora;Francesco P. D’Armiento;Gaetano De Rosa

  • Taxane-Based Combinations As Adjuvant Chemotherapy of Early Breast Cancer : A Meta-Analysis of Randomized Trials

    Michele De Laurentiis;Giuseppe Cancello;Diego D'Agostino;Mario Giuliano

  • Symptomatic Toxicities Experienced During Anticancer Treatment: Agreement Between Patient and Physician Reporting in Three Randomized Trials

    Massimo Di Maio;Ciro Gallo;Natasha B. Leighl;Maria Carmela Piccirillo

  • Antitumor Activity of ZD6474, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Human Cancer Cells with Acquired Resistance to Antiepidermal Growth Factor Receptor Therapy

    Fortunato Ciardiello;Roberto Bianco;Roberta Caputo;Rosa Caputo

  • Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer.

    Francesco Schettini;Francesco Schettini;Nuria Chic;Nuria Chic;Fara Brasó-Maristany;Fara Brasó-Maristany;Laia Paré

  • Antitumor Activity of Sequential Treatment with Topotecan and Anti-Epidermal Growth Factor Receptor Monoclonal Antibody C225

    Fortunato Ciardiello;Roberto Bianco;Vincenzo Damiano;Sonya De Lorenzo

  • A Meta-Analysis on the Interaction between HER-2 Expression and Response to Endocrine Treatment in Advanced Breast Cancer

    Michele De Laurentiis;Grazia Arpino;Grazia Arpino;Erminia Massarelli;Angela Ruggiero

  • Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial.

    Sandro Pignata;Giovanni Scambia;Dionyssios Katsaros;Ciro Gallo

  • Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials

    Richard Gray;Rosie Bradley;Jeremy Braybrooke;Zulian Liu

  • Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment

    Mario Giuliano;Mario Giuliano;Mario Giuliano;Antonio Giordano;Antonio Giordano;Summer Jackson;Kenneth R Hess

  • Epithelial–Mesenchymal Transition and Stem Cell Markers in Patients with HER2-Positive Metastatic Breast Cancer

    Antonio Giordano;Hui Gao;Simone Anfossi;Evan Cohen

  • Treatment of Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer Xenografts With Multiagent HER-Targeted Therapy

    Grazia Arpino;Carolina Gutierrez;Heidi Weiss;Mothaffar Rimawi

  • Perspective on Circulating Tumor Cell Clusters: Why It Takes a Village to Metastasize

    Mario Giuliano;Anum Shaikh;Hin Ching Lo;Grazia Arpino

  • Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect.

    Giampaolo Tortora;Rosa Caputo;Vincenzo Damiano;Davide Melisi

  • First-Line Trastuzumab Plus an Aromatase Inhibitor, With or Without Pertuzumab, in Human Epidermal Growth Factor Receptor 2–Positive and Hormone Receptor–Positive Metastatic or Locally Advanced Breast Cancer (PERTAIN): A Randomized, Open-Label Phase II Trial

    Mothaffar Rimawi;Jean-Marc Ferrero;Juan de la Haba-Rodriguez;Christopher Poole

  • Antitumor activity of combined treatment of human cancer cells with ionizing radiation and anti-epidermal growth factor receptor monoclonal antibody C225 plus type I protein kinase A antisense oligonucleotide.

    Cataldo Bianco;Roberto Bianco;Giampaolo Tortora;Vincenzo Damiano

Frequent Co-Authors

Riccardo Autorino
Riccardo Autorino Virginia Commonwealth University
Fortunato Ciardiello
Fortunato Ciardiello University of Campania "Luigi Vanvitelli"
Giampaolo Tortora
Giampaolo Tortora University of Verona
Francesco Cognetti
Francesco Cognetti Sapienza University of Rome
Stefano Pepe
Stefano Pepe University of Salerno
Sandro Pignata
Sandro Pignata National Cancer Institute
Sandro Barni
Sandro Barni Mario Negri Institute for Pharmacological Research
Antonio Giordano
Antonio Giordano Temple University
Pierfranco Conte
Pierfranco Conte University of Padua
Giovanni Scambia
Giovanni Scambia Catholic University of the Sacred Heart

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Aspiring medical professionals have a variety of online degree options that can support many career pathways beyond traditional medicine. For those interested in advancing nursing practice, there are many cheapest dnp programs online, making doctoral-level education more accessible and affordable.

Registered nurses seeking career advancement can pursue the rn to bsn cheapest programs, perfect for building critical skills and boosting job opportunities without a heavy financial burden.

For those who hold a non-nursing bachelor’s degree but want to transition into the nursing field, direct entry msn programs for non-nurses online offer a shortcut to becoming an advanced practice nurse in less time.

Additionally, students looking for a faster route into healthcare may benefit from online adn programs, which provide an accessible path to becoming a registered nurse.

Exploring these online degrees can open doors to a wide range of healthcare careers, offering flexibility and affordability for diverse student needs.

Best Scientists Citing Sabino De Placido

Trending Scientists